ABILIFY
ARIPIPRAZOLE
- Strength
- 2 mg/1
- Form
- Tablet
- Class
- Atypical Antipsychotic
Otsuka America Pharmaceutical, Inc.
Listed by Unichem Pharmaceuticals (USA), Inc.
| Dosage form | Tablet |
|---|---|
| Route | Oral |
| Drug class | Atypical Antipsychotic |
| Approval route | ANDA — approved generic |
| NDC code | 29300-180 |
| FDA application | ANDA203025 |
| RxNorm concept | 349490 |
| Package sizes listed | 3 |
| Marketed since | February 2022 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
ARIPIPRAZOLE
Otsuka America Pharmaceutical, Inc.
ARIPIPRAZOLE
Otsuka America Pharmaceutical, Inc.
ARIPIPRAZOLE
Otsuka America Pharmaceutical, Inc.
ARIPIPRAZOLE
Otsuka America Pharmaceutical, Inc.
ARIPIPRAZOLE
Otsuka America Pharmaceutical, Inc.
ARIPIPRAZOLE
Otsuka America Pharmaceutical, Inc.
Aripiprazole
Otsuka America Pharmaceutical, Inc
Aripiprazole
Otsuka America Pharmaceutical, Inc
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.